Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 10/20 | 0.50 |
| ▸ | PGR | P06401 | 7/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932715 | 0.92 | NR3C1 (0.53) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL1932477 | 0.89 | LMNA (0.48) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL291691 | 0.84 | NR3C1 (0.58) | NR3C1NR3C2PGRPDK1PDK2 | |
| SCHEMBL1932639 | 0.84 | NR3C1 (0.49) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL1932250 | 0.84 | NR3C1 (0.48) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL1932704 | 0.81 | NR3C1 (0.47) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL1931662 | 0.81 | P2RX1 (0.50) | NR3C1NR3C2PGRALDH1A1 | |
| SCHEMBL1932154 | 0.79 | NR3C1 (0.46) | NR3C1NR3C2PGR | |
| SCHEMBL1931572 | 0.79 | NR3C1 (0.49) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL291862 | 0.77 | NR3C1 (0.56) | NR3C1NR3C2PGRPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110137038-A1 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | BAUSCH & LOMB INCORPORATED | 2011-06-09 | — | — | US | disclosed |
| EP-2121670-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | Bausch & Lomb Incorporated (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2086921-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | Bausch & Lomb Incorporated (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008088969-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | BAUSCH & LOMB INCORPORATED (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171873-A1 | Synthesis of selected stereoisomers of certain substituted alcohols | BAUSCH & LOMB INCORPORATED | 2008-07-17 | — | — | US | disclosed |
| WO-2008060799-A2 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | BAUSCH & LOMB INCORPORATED (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080114172-A1 | Synthesis of Selected Stereoisomers of Certain Substituted Alcohols | BAUSCH & LOMB INCORPORATED | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114172-A1 | Synthesis of Selected Stereoisomers of Certain Substituted Alcohols | ADH1A, ADH1C, CYP2E1 | NR3C1 203/4885NR3C2 116/4885PGR 2372/4885 |
| US-20110137038-A1 | SYNTHESIS OF SELECTED STEREOISOMERS OF CERTAIN SUBSTITUTED ALCOHOLS | ADH1A, ADH1C, CYP2E1 | NR3C1 203/4885NR3C2 116/4885PGR 2372/4885 |
| US-20080171873-A1 | Synthesis of selected stereoisomers of certain substituted alcohols | ADH1A, ADH1C, ADH5 | NR3C1 74/4885NR3C2 37/4885PGR 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.